Trials / Not Yet Recruiting
Not Yet RecruitingNCT06092242
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tas-102(Suyuan) combined with bevacizumab | Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks. |
Timeline
- Start date
- 2023-10-15
- Primary completion
- 2025-10-15
- Completion
- 2027-10-15
- First posted
- 2023-10-23
- Last updated
- 2023-10-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06092242. Inclusion in this directory is not an endorsement.